PML-RARA Translocation, t(15;17)
Alternative name:
PML-RARA Fusion
Methodology
Molecular
Test Description and clinical significance
Genes
PML-RARA Translocation, t(15;17)
Disease:
Acute Promyelocytic Leukemia, invasive breast carcinoma, lung adenocarcinoma, and esophageal adenocarcinoma
Next generation sequencing of gene panel. The protein encoded by this gene is similar to FYN binding protein (FYB/SLAP-130), an adaptor protein involved in T cell receptor mediated signaling. This gene is expressed and regulated during normal myelopoiesis. The expression of this gene is induced by retinoic acid and is inhibited by the expression of PML-RARalpha, a fusion protein of promyelocytic leukemia (PML) and the retinoic acid receptor-alpha (RARalpha).
Specimen Requirements
Collection:
3 mL of EDTA, citrate (ACD) or Heparinized bone marrow and peripheral blood specimens for RNA gene fusion detection
Stability:
96hours/4 to 7 days refrigerated
Unacceptable Conditions:
Specimen submitted is in the incorrect fixative or anticoagulant. Specimen received after the stability date. Gross hemolysis. Frozen specimen. Insufficient specimen. Unlabeled. Left un-refrigerated for an extended period.
Storage & Transport
received within 96 hours of drawing. Samples that are 4 to 7 days old should be refrigerated.
CPT(s)
81315 for common breakpoints,
81316 for single breakpoint
New York Approved
NO
TAT
10 Days
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
